Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study

Saved in:
Bibliographic Details
Published inClinics (São Paulo, Brazil) Vol. 67; no. 3; pp. 283 - 287
Main Authors Batista, José Gomes, Soares, José Maria, Maganhin, Carla Cristina, Simões, Ricardo Santos, Tomaz, Geraldez, Baracat, Edmund Chada
Format Journal Article
LanguageEnglish
Portuguese
Published Brazil Elsevier España, S.L.U 01.01.2012
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Faculdade de Medicina / USP
Elsevier España
Subjects
Adult
Female
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Insulin Resistance - physiology
Insulin-Like Growth Factor Binding Protein 3 - metabolism
Insulin-Like Growth Factor I - metabolism
MEDICINE, GENERAL & INTERNAL
Pilot Projects
Polycystic Ovary Syndrome - drug therapy
Polycystic Ovary Syndrome - metabolism
Rapid Communication
Rosiglitazone
Statistics, Nonparametric
Thiazolidinediones - adverse effects
Thiazolidinediones - therapeutic use
Online AccessGet full text

Cover

More Information
Bibliography:Batista JG conducted the study, analyzed and interpreted the data, and drafted the paper. Soares-Jr JM analyzed the data, revised the draft of manuscript, and approved the version to be published. Maganhin CC analyzed the data and revised the draft. Baracat EC helped to conceive the study, analyze the data, and critically revise the manuscript for important intellectual content. Simões RS revised the final version of the paper. Tomaz G contributed to the conception and design, and to the acquisition, analysis, and interpretation of the data.
ISSN:1807-5932
1980-5322
1980-5322
DOI:10.6061/clinics/2012(03)14